In a context of global case reduction, the American laboratory seeks to adapt to new post-pandemic demands.
After the World Health Organization (WHO) will declare end of the Covid-19 pandemicthe different laboratories began to make changes regarding the treatment of this disease that caused so much havoc worldwide. Such is the case of modernwhich announced the reduced production of your vaccine against this virus.
The measure is due to decrease in cases at a global level, and to the creation of a new updated version of the dose, which would keep infections low while reducing production. Stephen Hogepresident of the company based in Massachusettsassured that this can be achieved only due to the “lower post-pandemic demand” that is seen both in United States as in the rest of the world.
According to what was confirmed by the company, the reduction in production will help Moderna adapt to the endemic phase of the diseasewhich also caused a decline in demand for vaccinesas buyers reduce orders for shots.
image.png
“In the last two years, we have been in pandemic mode producing billion doses per year“Hoge added. “We have been waiting for the moment when the pandemic is officially behind us to have to restructure that manufacturing footprint“he explained.
The company has the authorization of the Food and Drug Administration (FDA) of the United States for send doses to the entire country, and other agreements with countries such as United Kingdom, Canada and Japan. However, stillor has agreements with the European Union (EU).
Although Moderna is working on reducing production of the COVID vaccine, agreements with manufacturers could last until the next year. In this way, there are still months before the results of this measure can be seen.
More Moderna vaccines
The renowned laboratory is not only responsible for the production of vaccines against Covid-19, but also for fight other types of viruses. Such is the case of the vaccine against respiratory syncytial virus (VRS), an anti-flu drug that completed its regulatory submission a few days ago.
The objective of this dose is to generate a immune response more potent against the four strains A and B of the virus, compared to the traditional flu vaccines in a late-stage trial.
According to modernthe effectiveness of the flu vaccine was demonstrated in all age groups, including elderly patients. In addition to being safe and tolerable, a preliminary study showed that it was equal to or superior to Sanofi’s high-dose flu vaccine.
Source: Ambito
